Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• * *Neisseria meningitidis* serogroup B (MenB) is a significant global cause of meningitis and septicemia.
• * Early outer membrane vesicle (OMV) vaccines showed limited efficacy due to strain specificity and lack of durable immunity.
• * MenB disease poses a substantial public health challenge, necessitating effective prevention strategies.

Purpose of the Study:

• * To evaluate the potential of novel recombinant protein-based MenB vaccines for broader disease coverage.
• * To compare the advantages of recombinant vaccines over older OMV vaccines.
• * To advocate for optimal vaccination strategies, including routine use of MenB vaccines.

Main Methods:

• * Review of existing literature on MenB vaccines, including OMV and recombinant protein-based approaches.
• * Analysis of vaccine efficacy, strain coverage, and immune response characteristics.
• * Examination of vaccination strategies, contrasting reactive with routine use.

Main Results:

• * Recombinant protein-based MenB vaccines target conserved surface proteins, offering potential for broader strain coverage.
• * Older OMV vaccines were strain-specific and did not induce long-lasting immunity, limiting their widespread applicability.
• * Reactive vaccination strategies have proven inefficient due to delays and resource constraints.

Conclusions:

• * Recombinant protein-based MenB vaccines represent a significant advancement in preventing MenB disease.
• * Routine vaccination with these newer vaccines holds promise for substantially reducing the global burden of MenB disease.
• * Despite their potential, the routine use of MenB vaccines remains limited in current practice.